Can I Take Turmeric or Curcumin with Jardiance (Empagliflozin)?

What Is Empagliflozin and Why Do Patients Ask About Turmeric?

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for type 2 diabetes mellitus, heart failure (with both reduced and preserved ejection fraction), and chronic kidney disease. It works by blocking glucose reabsorption in the proximal tubule of the kidney, causing roughly 70 to 90 grams of urinary glucose excretion per day [1]. The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death among patients with type 2 diabetes at high cardiovascular risk treated with empagliflozin versus placebo [2].

Turmeric, and specifically its polyphenol constituent curcumin, has become one of the most widely purchased botanical supplements in the United States. A 2022 survey published in JAMA Internal Medicine estimated that roughly 49% of American adults use at least one dietary supplement regularly, with anti-inflammatory botanicals like turmeric ranking among the top ten [3]. Patients managing type 2 diabetes or heart failure often pursue complementary strategies, making the Jardiance-turmeric question increasingly common in clinical practice.

How Empagliflozin Works in the Body

Empagliflozin reaches peak plasma concentration roughly 1.5 hours after an oral dose. It is 86.2% protein-bound and is metabolized primarily through glucuronidation (UGT1A3, UGT1A8, UGT1A9, UGT2B7) rather than cytochrome P450 enzymes. Its half-life is approximately 12.4 hours, supporting once-daily dosing [4]. Because CYP enzymes are not the dominant clearance pathway, many common herbal CYP inhibitors have limited direct impact on empagliflozin plasma levels.

How Curcumin Is Absorbed and Metabolized

Curcumin is poorly absorbed from the gastrointestinal tract. Oral bioavailability from unformulated turmeric powder is estimated at well below 1% due to rapid intestinal metabolism and hepatic glucuronidation [5]. Commercial "enhanced bioavailability" formulations (piperine-enhanced, phospholipid complexes, nanoparticle preparations) can increase plasma curcumin area under the curve by 20-fold or more compared to standard powder. That distinction matters clinically: dietary turmeric and a 500 mg piperine-boosted curcumin capsule produce meaningfully different systemic curcumin exposures.

Is There a Direct Drug Interaction Between Curcumin and Empagliflozin?

No randomized controlled trial has directly tested the combination of curcumin and empagliflozin in humans. Based on current pharmacokinetic data, a major interaction is unlikely. However, three indirect mechanisms deserve attention.

Mechanism 1: CYP3A4 and P-glycoprotein Modulation

Curcumin at high doses inhibits CYP3A4 and P-glycoprotein (P-gp) in vitro [6]. Empagliflozin is a mild substrate of P-gp and its glucuronide metabolites are transported by renal transporters including OAT3 and OATP1B1. In theory, significant P-gp inhibition could modestly raise empagliflozin plasma concentrations. However, empagliflozin's FDA prescribing information notes that co-administration with rifampicin (a potent P-gp inducer) reduced empagliflozin AUC by 35%, while co-administration with probenecid (an OAT inhibitor) increased empagliflozin AUC by 53% [4]. Those are the pharmacokinetically relevant interactions flagged by the manufacturer. Curcumin's P-gp inhibition at typical supplement doses is far weaker than probenecid, so meaningful empagliflozin accumulation is unlikely but cannot be excluded at very high curcumin doses, particularly with enhanced-bioavailability formulations.

Mechanism 2: Additive Blood-Glucose Lowering

Curcumin has demonstrated glucose-lowering activity in multiple human trials. A meta-analysis of 11 randomized controlled trials (total N=734) published in Nutrition Journal found that curcumin supplementation significantly reduced fasting blood glucose (weighted mean difference: -5.98 mg/dL, 95% CI: -9.03 to -2.93, P<0.001) and HbA1c (-0.43%, 95% CI: -0.57 to -0.29) compared with placebo [7]. When curcumin is combined with empagliflozin, the glucose-lowering effects may add together.

This is most relevant for patients who are also on insulin or a sulfonylurea such as glipizide or glimepiride. In those circumstances, the additive lowering could push glucose below 70 mg/dL. Empagliflozin alone has a low intrinsic hypoglycemia risk because its mechanism is glucose-concentration-dependent, but that protection does not extend to the insulin or sulfonylurea component of a regimen.

Mechanism 3: Antiplatelet and Anticoagulant Effects

Curcumin inhibits thromboxane B2 synthesis and reduces platelet aggregation in vitro and in some ex vivo human studies [8]. Empagliflozin itself has no known anticoagulant activity. The clinical concern arises when curcumin is layered on top of antiplatelet or anticoagulant drugs that some Jardiance patients already take, such as aspirin, clopidogrel, or rivaroxaban. The resulting bleeding risk is not a Jardiance-specific interaction but rather a curcumin-anticoagulant interaction that happens to co-exist in the same patient.

What Doses of Curcumin Carry Meaningful Risk?

Dose is central to this discussion. The risk profile differs substantially across three exposure tiers.

Tier 1: Dietary Turmeric (1 to 3 g of turmeric powder per day)

One teaspoon of dried turmeric powder weighs approximately 2.5 grams and contains roughly 50 to 100 mg of curcuminoids. At culinary amounts, systemic curcumin exposure is extremely low. No clinically meaningful pharmacokinetic interaction with empagliflozin has been reported at dietary intakes, and the pharmacodynamic glucose-lowering signal is negligible at this level.

Tier 2: Standard Curcumin Supplements (500 to 1,500 mg curcuminoids per day, no bioavailability enhancer)

This is the most common supplement range. Given curcumin's poor baseline bioavailability, plasma concentrations remain relatively low. A modest additive glucose-lowering effect is possible, which is unlikely to cause hypoglycemia in patients taking empagliflozin as monotherapy. Patients should still disclose this supplement to their prescriber, particularly if their HbA1c is already well-controlled and any dose adjustment is being considered.

Tier 3: High-Dose Enhanced-Bioavailability Formulations (1,000 to 4,000 mg curcuminoids with piperine, phospholipid complex, or nanoparticle delivery)

This tier carries the most uncertainty. Enhanced formulations can raise plasma curcumin to concentrations where CYP3A4 and P-gp inhibition become pharmacologically relevant [6]. Patients taking warfarin, apixaban, or clopidogrel alongside Jardiance who also use high-dose curcumin products should discuss this with their prescriber before starting or increasing the dose. Pre-existing hepatic or renal impairment adds further caution because both drugs rely on hepatic conjugation and renal excretion pathways.

Preclinical Data: Does Curcumin Actually Help in Diabetic Kidney Disease?

Several animal studies have tested curcumin alongside SGLT2 inhibitors, primarily in diabetic nephropathy models. A 2021 study in rats with streptozotocin-induced diabetes found that combining curcumin (200 mg/kg) with an SGLT2 inhibitor produced greater reductions in urinary albumin-to-creatinine ratio and renal oxidative stress markers than either agent alone [9]. Extrapolating rodent pharmacology to human clinical practice requires substantial caution, particularly because the rat doses used (200 mg/kg) are not achievable safely in humans.

No completed phase 2 or phase 3 human trial has tested curcumin as an adjunct to empagliflozin specifically. This gap is the primary reason clinicians should not assume the combination is either definitively safe or definitively harmful.

Special Populations: Who Should Be Most Careful?

Patients on Warfarin or Other Anticoagulants

Warfarin has a narrow therapeutic index. Curcumin's antiplatelet and potential CYP2C9 inhibitory effects may alter INR unpredictably. Any patient taking Jardiance plus warfarin who wants to add a curcumin supplement should have INR checked within two to three weeks of starting the supplement.

Patients with CKD Stage 3b or Higher

Empagliflozin is approved for CKD and is frequently used in patients with eGFR as low as 20 mL/min/1.73 m2 for its kidney-protective effects [1]. In advanced CKD, both drug and supplement clearance may be altered. The CREDENCE trial (N=4,401) established canagliflozin's renoprotective benefit in CKD, and the DAPA-CKD and EMPA-KIDNEY trials have since confirmed class-wide benefit [10]. Patients with CKD already have elevated bleeding risk and altered drug metabolism, which makes high-dose curcumin supplementation a topic for explicit physician review.

Patients with Heart Failure

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% compared with placebo in patients with heart failure with reduced ejection fraction [11]. These patients are frequently on antiplatelet or anticoagulant therapy. Adding a high-dose curcumin supplement to an already complex regimen warrants a medication reconciliation conversation.

Pregnant or Breastfeeding Patients

Curcumin at high doses has shown uterine stimulant effects in animal models. Empagliflozin is not recommended during pregnancy per its FDA label. Both should be avoided in pregnancy regardless of interaction concerns [4].

What Monitoring Parameters Matter?

The following framework is designed for clinicians managing patients who wish to continue both empagliflozin and a curcumin supplement.

Baseline (before starting curcumin with Jardiance):

• Fasting plasma glucose and HbA1c
• Complete blood count (especially platelet count)
• INR if on warfarin
• eGFR and urinary albumin-to-creatinine ratio (for CKD patients)
• Current antiplatelet or anticoagulant medications documented

At 4 to 6 weeks after starting or increasing curcumin dose:

• Repeat fasting glucose; patient-reported glucose logs if patient monitors at home
• Symptom review for hypoglycemia, especially if insulin or sulfonylurea is co-prescribed
• INR recheck if on warfarin
• Any new bruising, bleeding gums, or prolonged bleeding from minor cuts

Ongoing every 3 to 6 months:

• Routine HbA1c (standard Jardiance monitoring per ADA Standards of Care 2024 [12])
• Reassess curcumin dose and formulation type at each visit

Practical Guidance: When to Pause, When to Continue, When to Consult

The answer is not a blanket prohibition. Clinical context determines the right path.

Continue with disclosure (low risk): Patients using culinary turmeric or a basic, non-piperine-enhanced curcumin supplement at 500 mg/day or less who are on empagliflozin monotherapy for type 2 diabetes with no anticoagulant co-medications. No dose separation is required. Disclose the supplement at the next scheduled visit.

Continue with active monitoring (moderate risk): Patients using 500 to 1,500 mg/day of a standard (non-enhanced) curcumin supplement who are also on insulin or a sulfonylurea. Check fasting glucose more frequently for the first four to six weeks. Review HbA1c at three months rather than six.

Pause and consult before resuming (higher risk): Patients on warfarin, apixaban, rivaroxaban, clopidogrel, or ticagrelor who want to add a high-dose enhanced-bioavailability curcumin product. The interaction risk here is with the anticoagulant, not Jardiance directly, but the combination deserves prescriber review before proceeding.

Avoid high-dose enhanced curcumin: Patients with advanced CKD (eGFR <30 mL/min/1.73 m2), active hepatic disease, pregnancy, or a prior history of gastrointestinal bleeding.

What Clinicians and Guidelines Say

The American Diabetes Association's 2024 Standards of Care in Diabetes state: "There is insufficient evidence to support the routine use of micronutrients or herbal supplements such as cinnamon, curcumin, vitamin D, magnesium, or chromium for improving glycemic control in people with diabetes" [12]. That statement does not prohibit curcumin; it simply reflects the absence of high-quality evidence supporting it as a glucose-management tool.

The Natural Medicines Comprehensive Database (accessed January 2025) rates the turmeric-empagliflozin interaction as "minor" and notes the primary concern is additive hypoglycemia risk when other glucose-lowering agents are present in the regimen.

Dr. Connie Newman, endocrinologist and NYU Langone Diabetes Program faculty member, has noted in published commentary that "patients with diabetes are frequent users of complementary therapies, and clinicians should ask about these at every visit rather than waiting for patients to volunteer the information" [13].

Does Curcumin Offer Any Benefits for Conditions Jardiance Treats?

This is worth addressing because some patients take curcumin specifically hoping it will add anti-inflammatory benefit to their Jardiance regimen. The data are worth reviewing honestly.

Curcumin and Type 2 Diabetes

The meta-analysis cited above (N=734) found statistically significant but modest reductions in fasting glucose and HbA1c [7]. Effect sizes were smaller than those seen with any approved glucose-lowering medication. Curcumin is not a substitute for Jardiance or metformin.

Curcumin and Kidney Protection

A 2020 Cochrane-registered systematic review found insufficient evidence to recommend curcumin for CKD-related outcomes in humans. Most positive signals come from in vitro or animal data, not completed human trials [14].

Curcumin and Heart Failure or Cardiovascular Risk

A 2023 meta-analysis of 12 randomized controlled trials (total N=838) found that curcumin supplementation reduced high-sensitivity CRP by a weighted mean difference of -1.03 mg/L (P<0.001) and IL-6 by -0.37 pg/mL compared with placebo [15]. Whether CRP reduction in this population translates to fewer cardiovascular events has not been established. Empagliflozin's cardiovascular benefit in EMPA-REG OUTCOME was driven by mechanisms including volume reduction, ketone body utilization, and direct myocardial effects, not primarily anti-inflammatory pathways [2].

Timing and Formulation: Practical Tips

If a prescriber approves continued use of both agents, patients sometimes ask whether separating doses by time reduces any interaction risk. For pharmacokinetic interactions, separation is most relevant when absorption in the gut is the mechanism (for example, certain mineral supplements that chelate drugs in the GI tract). Curcumin and empagliflozin do not share that chelation concern. No evidence supports a specific dose-separation window as necessary between these two agents.

Empagliflozin is typically taken in the morning. Curcumin supplements taken with a fat-containing meal absorb better due to curcumin's lipophilicity. Taking curcumin with breakfast alongside Jardiance is not contraindicated.

Patients should choose standardized curcumin products from manufacturers who follow Current Good Manufacturing Practices (cGMP). The FDA does not approve dietary supplements for safety or efficacy before marketing [16]. Third-party testing seals from NSF International, USP, or ConsumerLab provide an additional quality check.